Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.25%||162.64||0.7%||$1229.36m|
|MRK||Merck & Co., Inc.||0.18%||77.61||0.7%||$782.74m|
|BMY||Bristol-Myers Squibb Co.||0.44%||65.75||1.0%||$703.61m|
|LLY||Eli Lilly & Co.||0.25%||189.73||1.1%||$539.14m|
|RPRX||Royalty Pharma Plc||-0.24%||41.77||0.2%||$91.76m|
|NVO||Novo Nordisk A/S||0.75%||72.71||0.1%||$62.90m|
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.